# Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer

> **NCT07680088** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 17 (estimated)

## Conditions studied

- Anal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07680088
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680088, "Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07680088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*